CBIO vs MRK vs JPM vs KO

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Crescent Biopharma, Inc. (CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus The Coca-Cola Company at 27. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +110. 0%, compared to -93. 3% for Crescent Biopharma, Inc. (CBIO). Over 10 years, the gap is even starker: JPM returned +465. 8% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately -571% more volatile than KO relative to the S&P 500. On balance sheet safety, Crescent Biopharma, Inc. (CBIO) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -815. 0% for Crescent Biopharma, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 1x forward P/E versus 25. 2x for The Coca-Cola Company — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CBIO: 79. 9% to $33. 00.

In this comparison, MRK (2.

7% yield), KO (2. 5% yield), JPM (1. 9% yield) pay a dividend. CBIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, CBIO: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CBIO (Healthcare) and MRK (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CBIO is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. MRK, JPM, KO pay a dividend while CBIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.